| 查看: 693 | 回复: 11 | |||
[交流]
【深容SCI写作智能体】Abstract实测
|
|||
|
【深容SCI写作智能体】Abstract实测 如需试用【深容SCI写作智能体】,请联系深容张老师:shenrongagent [https://scioriginal.com] 上月深容推出了【深容SCI写作智能体】的Method,Introduction,Discussion智能体,写作质量非常高,全部真实参考文献,深受用户欢迎。 今天介绍的Abstract写作智能体,功能相对简单,根据用户提供的正文内容,快速起草摘要,同时输出结构式摘要和一体式摘要。 1. 用户输入正文内容: 2. 检索参考同类题材的摘要格式: 3. 输出结果Abstract。 智能体的写作质量非常高: (1) Structured ABSTRACT 1) Background Signal Transducer and Activator of Transcription 2 (STAT2) is well-known for its role in type I interferon (IFN-I) signaling, which is generally considered tumor-suppressive. However, its direct role in cancer, particularly colorectal cancer (CRC), remains underexplored. Given the critical involvement of immune and cytokine networks in CRC progression, elucidating STAT2's contribution is essential. 2) Methods We analyzed TCGA-COAD datasets to assess STAT2 and IFNAR1 expression and patient survival. Human HCT116 and murine MC38 cell lines with STAT2 or IFNAR1 knockouts were generated using CRISPR\/Cas9 technology. Cell proliferation was measured in vitro using the CellTiter 96 assay. In vivo tumor growth was evaluated by subcutaneous injection of knockout and control cells into immunodeficient or immunocompetent mice. Western blot and qPCR analyses were performed to assess downstream signaling and gene expression changes. 3) Results High STAT2 expression in TCGA-COAD tumors correlated with reduced patient survival, independent of IFNAR1 levels. STAT2 deletion impaired cell proliferation and tumor growth in both human and murine models, whereas IFNAR1 deletion did not. STAT2 KO cells exhibited reduced STAT1 activation but enhanced STAT3 phosphorylation, indicating distinct downstream signaling effects compared to IFNAR1 KO cells. These findings suggest that STAT2 promotes tumorigenicity through mechanisms distinct from canonical IFN-I signaling. 4) Conclusion Our study reveals that STAT2 functions as a tumor-promoting factor in CRC, acting independently of IFNAR1-mediated IFN-I signaling. Targeting STAT2 or its downstream pathways may offer a novel therapeutic strategy for mitigating CRC progression. --- (2) Integrated ABSTRACT Signal Transducer and Activator of Transcription 2 (STAT2) is a key mediator of type I interferon (IFN-I) signaling, traditionally viewed as tumor-suppressive. However, its direct role in colorectal cancer (CRC) remains poorly defined, despite the critical influence of immune and cytokine networks on disease progression. To address this gap, we analyzed TCGA-COAD datasets and found that high STAT2 expression in CRC tumors correlated with reduced patient survival, independent of IFNAR1 levels. Using CRISPR\/Cas9 technology, we generated human HCT116 and murine MC38 cell lines with STAT2 or IFNAR1 knockouts. In vitro cell proliferation assays demonstrated that STAT2 deletion significantly impaired growth, whereas IFNAR1 deletion had no effect. In vivo studies in immunodeficient and immunocompetent mice confirmed that STAT2 KO cells formed smaller tumors compared to controls, while IFNAR1 KO cells did not differ significantly from wild-type cells. Western blot and qPCR analyses revealed that STAT2 deletion reduced STAT1 activation but enhanced STAT3 phosphorylation, indicating distinct downstream signaling effects compared to IFNAR1 KO cells. These findings suggest that STAT2 promotes tumorigenicity through mechanisms independent of canonical IFN-I signaling. Our study highlights STAT2 as a potential therapeutic target in CRC, offering new avenues for mitigating disease progression by targeting its pro-tumorigenic pathways. 以上这篇Abstract起草时间仅00:01:35 【深容SCI写作智能体】包括四大模块:Method智能体、Introduction智能体、Discussion智能体、Abstract智能体。 如需试用智能体,请徽售联系深容张老师:shenrongagent [https://scioriginal.com] #SCI论文 #科研 #实验 #博士 #投稿 |
» 猜你喜欢
27年药学 考博申请
已经有6人回复
征友后感触
已经有8人回复
注意啦!用基金购买打印纸、硒鼓、优盘、移动硬盘、个人计算机属于违规了
已经有4人回复
为了不被淘汰,必须要开始第三次奋斗了
已经有12人回复
IVD领域内综述投稿推荐
已经有5人回复
售SCI一区T0P文章,我:8.O.55.1.O54,科目全,可伽急
已经有3人回复
简单回复
夏末末872楼
2026-01-11 18:20
回复
pheiphei2025(金币+1): 谢谢参与
1 发自小木虫手机客户端
2026-01-11 18:31
回复
jiaoxg4楼
2026-01-11 18:39
回复
pheiphei2025(金币+1): 谢谢参与




tfang5楼
2026-01-11 18:42
回复
pheiphei2025(金币+1): 谢谢参与
2026-01-11 18:51
回复
pheiphei2025(金币+1): 谢谢参与
2026-01-11 19:04
回复
toppaper8楼
2026-01-11 20:07
回复
XG-WUST9楼
2026-01-11 21:35
回复
pheiphei2025(金币+1): 谢谢参与
up 发自小木虫IOS客户端
psylhh10楼
2026-01-11 22:21
回复
pheiphei2025(金币+1): 谢谢参与
庚辰辛丑11楼
2026-01-12 07:28
回复
pheiphei2025(金币+1): 谢谢参与
afit88812楼
2026-01-12 11:17
回复










回复此楼